Cesarone M R, Laurora G, De Sanctis M T, Incandela L, Grimaldi R, Marelli C, Belcaro G
Istituto di Clinica Cardiovascolare, Università degli Studi G. D'Annunzio, Chieti.
Minerva Cardioangiol. 1994 Jun;42(6):299-304.
In 87 patients with chronic venous hypertensive microangiopathy the efficacy of oral FTTCA (Centella asiatica) administered for 60 days was tested. The microcirculatory effects of two dosages (30 mg bid and 60 mg bid) versus placebo was assessed in a double blind study. The compound was well tolerated and no unwanted effects were observed. Microcirculatory parameters--peri-malleolar skin flux at rest (RF) and transcutaneous PO2 and PCO2--improved as did the abnormally increased RF, PCO2 decreased and PO2 increased in comparison with values measured at inclusion. These results confirm the efficacy of FTTCA in venous hypertensive microangiopathy. Furthermore the effects of FTTCA appear to be dose-related.
对87例慢性静脉高压性微血管病患者进行了为期60天的口服积雪草总苷（积雪草）疗效测试。在一项双盲研究中评估了两种剂量（每日两次，每次30毫克和每日两次，每次60毫克）与安慰剂相比的微循环效应。该化合物耐受性良好，未观察到不良影响。微循环参数——静息时内踝周围皮肤血流量（RF）、经皮氧分压和二氧化碳分压——均有所改善，与入组时测量值相比，异常升高的RF降低，二氧化碳分压降低，氧分压升高。这些结果证实了积雪草总苷在静脉高压性微血管病中的疗效。此外，积雪草总苷的作用似乎与剂量相关。
